BIOHAVEN AND PFIZER PARTNER TO MARKET MIGRAINE DRUGS OUTSIDE THE US
Pfizer has signed a collaboration and licence agreement to obtain rights to market Biohaven Pharmaceutical’s migraine drugs, rimegepant and zavegepant, outside the US.
An oral calcitonin gene-related peptide receptor antagonist (CGRP), rimegepant is marketed as Nurtec ODT in the US region
The drug is also indicated as preventive therapy in adults with episodic migraine.
The EMA and other regulatory agencies outside the US are currently reviewing applications seeking approval for rimegepant.
An increased affinity small molecule CGRP receptor antagonist, zavegepant is being analysed in an intranasal delivery and a soft-gel formulation in Phase III trials for treating migraine.
covid-19
Merchandise trade volume to rise in 2021
The World Trade Organization forecasts the merchandise trade volume to rise by 10.8% in 2021